A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01)

Lignende værker

• Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
  af: Patel, Sapna, et al.
  Udgivet: (2014)
• A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
  af: Clark, Joseph I., et al.
  Udgivet: (2018)
• A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
  af: Meghan J. Mooradian, et al.
  Udgivet: (2018-05-01)
• A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
  af: Mooradian, Meghan J., et al.
  Udgivet: (2018)
• High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
  af: Dutcher, Janice P, et al.
  Udgivet: (2014)